![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PROVENGE HELPS PATIENTS WITH ADVANCED PROSTATE CANCER
PROVENGE HELPS PATIENTS WITH ADVANCED PROSTATE CANCER
Dendreon has announced that the analysis of the final three-year survival data of its second Phase III study of Provenge-an investigational active immunotherapy for the treatment of prostate cancer-showed a survival benefit in men with advanced prostate cancer who were treated with Provenge. Prostate cancer is the most commonly diagnosed non-skin cancer in the U.S. and the third most common cancer worldwide.
In the study, the three-year final survival analysis in the intent-to-treat population of the double-blind, placebo-controlled study of Provenge in 98 men with asymptomatic, metastatic, androgen-independent (hormone-refractory) prostate cancer showed a 20 percent improvement in median survival, compared to a placebo. In addition, at the three-year final follow up, the percentage of patients alive in the Provenge-treated group was substantially greater than the percentage of patients alive who received a placebo.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct